Cost-effectiveness analysis of metformin+dipeptidyl peptidase-4 inhibitors compared to metformin+sulfonylureas for treatment of type 2 diabetes

BACKGROUND: Patients with type 2 diabetes (T2D) typically use several drug treatments during their lifetime. There is a debate about the best second-line therapy after metformin monotherapy failure due to the increasing number of available antidiabetic drugs and the lack of comparative clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Christina S., Seoane-Vazquez, Enrique, Rodriguez-Monguio, Rosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796582/
https://www.ncbi.nlm.nih.gov/pubmed/29391064
http://dx.doi.org/10.1186/s12913-018-2860-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796582/
https://www.ncbi.nlm.nih.gov/pubmed/29391064
http://dx.doi.org/10.1186/s12913-018-2860-0

Ejemplares similares